Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-Targeted [In-111] Trillium Compound + PTI-122
- Development stage
- Unknown
- Lead developer
- Ratio Therapeutics
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
A combination therapy composed of a PSMA-targeted [In-111] Trillium Compound, which is a radiolabeled peptide conjugate that selectively targets prostate-specific membrane antigen (PSMA) on prostate cancer cells, and PTI-122, a small molecule cytoprotective agent. The PSMA-targeted Trillium Compound is designed for imaging and potentially for radiotherapeutic delivery, utilizing the radioactive isotope indium-111 to visualize and characterize PSMA-expressing tumors in men with metastatic prostate cancer. PTI-122 is co-administered to reduce potential toxicity and enhance safety. This combination is being developed for use in early-phase trials to improve tumor uptake and minimize off-target effects, aiming to inform dosing and optimize future therapeutic use of PSMA-directed radiopharmaceuticals in prostate cancer[1][2][3][5][6][7][8].
- Other names
- PSMA-Targeted [In-111]-Labeled Trillium Compound + PTI-122
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on PSMA-Targeted [In-111] Trillium Compound + PTI-122.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA-Targeted [In-111] Trillium Compound + PTI-122.